FDA insists on more women in drug trialsBMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7112.831f (Published 04 October 1997) Cite this as: BMJ 1997;315:831
- Deborah Josefson
- San Francisco
The Food and Drug Administration in the United States has proposed new regulations to force drug companies to include women in all phases of clinical trials.
Although women constitute roughly half of the population, traditionally both drug companies and the government have excluded many women from participating in trials of new drugs because of fears that they may induce teratogenic damage to a developing fetus. Additionally, drug companies have been worried that a woman's hormonal cycles could interfere with the metabolism and efficacy of some treatments. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial